The document discusses lead identification in drug development. It defines a lead compound as one that shows desired pharmaceutical activity and could potentially be developed into a drug. The document outlines the content to be presented, including an introduction to lead identification, what a lead is, properties of leads, and methods for identifying leads. Key methods discussed are random screening, non-random screening, high-throughput screening, and structure-based drug design.
Ethical considerations in Clinical Research Dr Ankita.pptxClinosolIndia
油
Ethical considerations are paramount in clinical research to protect the rights, well-being, and confidentiality of participants, as well as to ensure data integrity and maintain public trust. Here are some key ethical considerations in clinical research:
Informed Consent: Obtaining informed consent from participants is crucial. Participants should receive clear, understandable information about the study purpose, procedures, potential risks and benefits, alternatives, confidentiality measures, and their right to withdraw at any time. Informed consent should be voluntary, free from coercion, and obtained prior to participation.
Institutional Review Board (IRB) Approval: All clinical research involving human participants must undergo review by an independent IRB or ethics committee. The IRB evaluates the study's ethical implications, participant protections, study design, and informed consent process to ensure that the benefits of the research outweigh the potential risks.
Participant Safety and Monitoring: Safeguarding participant safety is paramount. Researchers should monitor participants closely, promptly address any adverse events or risks, and have protocols in place for participant safety and medical care. Regular safety monitoring and data analysis should be conducted throughout the study.
Data Privacy and Confidentiality: Protecting participant privacy and ensuring data confidentiality are critical. Researchers must adhere to applicable data protection regulations and establish robust measures to safeguard participant data, including de-identification, encryption, secure data storage, and restricted access. Only authorized personnel should have access to identifiable participant information.
Data Integrity and Transparency: Maintaining data integrity is essential for reliable research outcomes. Researchers should accurately collect, record, and report data, adhering to Good Clinical Practice (GCP) guidelines. Data should be analyzed objectively and reported transparently, avoiding any selective or biased reporting that could compromise the scientific integrity of the study.
Equity and Fairness: Clinical research should be conducted in a manner that promotes equity and fairness. Participants should be recruited and selected based on scientifically justified criteria, without discrimination or bias. Efforts should be made to ensure diverse representation in research studies to avoid underrepresentation of certain populations.
Post-trial Access: Participants should have the opportunity to access the study intervention or any relevant follow-up care once the trial is completed, particularly if the intervention has demonstrated significant benefit. Researchers should consider post-trial access in the study design and communicate the availability of such access to participants during the informed consent process.
The rapid increase in throughput of next generation sequencing (NGS) platforms is changing the genomics landscape. Typically, adapters containing sample indexes are added during library construction to allow multiple samples to be sequenced in parallel. Some strategies also introduce a unique molecular identifier (UMI) within the adapter to correct for PCR and sequencing errors. When a UMI is added, reads are assigned to each sample based on their associated sample index, and the UMI is used for error correction during data analysis. For simplicity, a single adapter that is suitable for a variety of applications would be ideal.
xGen速 Dual Index UMI Adapters take the guesswork out of adapter design and ordering. These adapters, created for Illumina sequencers, are compatible with standard library preparation methods and may be sequenced in different modes depending on your application. In addition to unique, dual indexes, the adapters contain a molecular barcode in an optional read position. We will discuss how unique, dual indexes mitigate sample index hopping for multiplexed sequencing and demonstrate how UMIs reduce false positives to improve detection of low-frequency variants.
This document provides an overview of phylogenetic analysis, including:
1) Phylogenetic analysis involves inferring evolutionary relationships between taxa by building phylogenetic trees and analyzing character evolution.
2) Phylogenetic trees show the branching patterns and relationships between taxa, with internal nodes representing hypothetical ancestors.
3) Phylogenetic analysis can provide insights into questions like human evolution, disease transmission, and the origins of genetic elements.
GLP and GMP are quality systems concerned with organizing and documenting the testing and manufacturing of products like pharmaceuticals, pesticides, and chemicals.
GLP applies to nonclinical safety studies and helps ensure data submitted to regulators is valid. It originated in the 1970s in response to cases like Industrial Bio Test, which falsified lab results. GLP principles cover the organization, facilities, equipment, standard operating procedures, performance, reporting, and record keeping of studies.
GMP aims to consistently produce quality products by having quality control systems in place and following manufacturing procedures. It is designed to minimize risks that cannot be eliminated through testing. The ten GMP principles include facility design, written procedures, documentation, validation, monitoring
This document provides an overview of phylogenetic analysis concepts and methods. It begins with an introduction to phylogenetic trees and their components. It then covers two main approaches to building trees - using distance methods like neighbor-joining and using optimality criteria like maximum parsimony. Key steps in both approaches like multiple sequence alignment and tree-building algorithms are described. The document concludes with discussing tools for evaluating tree reliability through bootstrapping and exploring available phylogenetics programs.
Ethics in Clinical Research: Challenges and SolutionsClinosolIndia
油
Ethics in clinical research is of paramount importance to protect the rights, safety, and well-being of human participants involved in studies. However, there are several challenges that researchers and regulatory bodies face in ensuring ethical practices. Let's discuss some of these challenges and potential solutions
Toxicogenomics is a field that combines genomics, transcriptomics, proteomics, and metabolomics with toxicology to understand how the genome responds to environmental stressors and toxicants. It aims to understand the relationship between environmental toxins and disease, identify biomarkers of exposure and toxicity, and elucidate molecular toxicity mechanisms. While it provides useful databases of environmental and genomic data, toxicogenomics analysis faces challenges in integrating different types of large datasets and linking "omics" data to specific health effects.
Sequence alignment involves identifying corresponding portions of biological sequences, such as DNA, RNA, and proteins, in order to analyze similarities and differences at the level of individual bases or amino acids. This can provide insights into structural, functional, and evolutionary relationships. Sequence alignment has many applications, including searching databases for similar sequences, constructing phylogenetic trees, and predicting protein structure. It works by designing an optimal correspondence between sequences that preserves the order of residues while maximizing matches and minimizing mismatches. Quantitative measures of sequence similarity, such as Hamming distance and Levenshtein distance, calculate the number of differences between aligned sequences.
This document discusses the t test and its variations. It describes the t test as a statistical significance test introduced in 1908. The t test can be used to test single or double sample means and the significance of observed values. There are different types of t tests, including one sample t tests, independent samples t tests, and paired t tests. The document reviews the assumptions, formulas, and steps to perform the different t tests, noting they can now be easily conducted with computers.
Satyaki Aparajit Mishra presented on the topic of standard error and predictability limits. Standard error is used to estimate the standard deviation from a sample. It is calculated by dividing the standard deviation by the square root of the sample size. A larger standard error means the sample mean is less reliable at estimating the population mean. Standard error helps determine how far sample estimates may be from the true population values. Mishra discussed estimating standard error from a single sample and how standard error is used to test hypotheses. He provided an example of testing if a coin flip was unbiased using the standard error of the proportion of heads observed.
PubMed is a free database of over 23 million citations and abstracts for biomedical literature from Medline, life sciences journals, and online books. It is maintained by the National Center for Biotechnology Information (NCBI) at the U.S. National Library of Medicine (NLM). PubMed provides bibliographic information and links to full-text content from publishers and libraries. Users can search PubMed using keywords, controlled vocabularies like MeSH, or advanced search techniques and filters to find relevant journal articles and resources.
Signal Management and Risk Assessment in PharmacovigilanceClinosolIndia
油
Signal management and risk assessment are critical components of pharmacovigilance, aimed at identifying and evaluating potential safety concerns associated with medicinal products. These processes help ensure the ongoing monitoring of product safety and the implementation of appropriate risk minimization strategies. Here's an overview of signal management and risk assessment in pharmacovigilance:
Signal Management:
A signal in pharmacovigilance refers to information that suggests a potential causal relationship between a medicinal product and an adverse event, either previously unrecognized or incompletely understood. Signal management involves the systematic detection, evaluation, and response to these potential safety signals. The goal is to determine whether further investigation is warranted and to take appropriate actions to mitigate risks if necessary.
Signal Management Process:
Signal Detection: Signals can be detected through various methods, including spontaneous reporting databases, literature review, data mining techniques, and cumulative analysis of safety data. Unusual patterns, unexpected associations, or an increase in the frequency of specific adverse events may trigger the need for further investigation.
Signal Evaluation: Once a signal is detected, it undergoes a comprehensive evaluation. This involves analyzing available data, conducting causality assessments, reviewing clinical trial results, and considering factors such as patient demographics, medical history, and concomitant medications.
Signal Validation: Validating a signal involves confirming its credibility and clinical relevance. This step may require additional data collection, case validation, and collaboration between various stakeholders, including regulatory authorities.
Signal Prioritization: Not all signals warrant the same level of attention. Signals are prioritized based on factors such as the severity of the adverse event, the strength of the association, and the potential impact on patient safety.
Risk-Benefit Assessment: A thorough benefit-risk assessment is conducted to weigh the potential risks associated with the signal against the known benefits of the medicinal product. This assessment informs regulatory decisions and the need for further actions.
Risk Minimization: If the signal is deemed credible and significant, risk minimization strategies may be implemented. These strategies could include changes to product labeling, communication to healthcare professionals and patients, and other measures to ensure the safe use of the product.
This document discusses correlation and different aspects of studying correlation. It defines correlation as the association or relationship between two variables that do not cause each other. It describes different types of correlation including positive, negative, linear, non-linear, simple, multiple and partial correlation. It also discusses various methods of studying correlation including graphic methods like scattered diagrams and correlation graphs, and algebraic methods like Karl Pearson's correlation coefficient and Spearman's rank correlation coefficient. The document explains concepts like coefficient of determination and hypothesis testing in correlation. It emphasizes that correlation indicates association but does not necessarily imply causation between variables.
Introduction
Definition
History
Principle
Components of bioinformatics
Bioinformatics databases
Tools of bioinformatics
Applications of bioinformatics
Molecular medicine
Microbial genomics
Plant genomics
Animal genomics
Human genomics
Drug and vaccine designing
Proteomics
For studying biomolecular structures
In- silico testing
Conclusion
References
FDA Guidelines for Drug Development & Approvalrahimbrave
油
The document discusses the drug development and approval process in the United States. It describes the roles and responsibilities of the Food and Drug Administration (FDA) in regulating drugs, medical devices, and other products. It then outlines the various phases of clinical trials (Phases I-IV) that drugs must go through to test for safety and efficacy before FDA approval. It also discusses the processes for approving generic drugs, biological products, and modifications to approved drugs.
The document discusses the history and definition of degrees of freedom. It states that the earliest concept of degrees of freedom was noted in the 1800s in the works of mathematician Carl Friedrich Gauss. The modern understanding was developed by statistician William Sealy Gosset in 1908, though he did not use the term. The term "degrees of freedom" became popular after English biologist Ronald Fisher began using it in 1922 when publishing reports on his work developing chi squares. Degrees of freedom represent the number of values in a study that can vary freely. They are important for understanding chi-square tests and the validity of the null hypothesis.
Automating the ACMG Guidelines with VSClinicalGolden Helix
油
Clinical Genetic testing requires a complex analysis using the totality of our knowledge about the clinical relevance of a variant and a gene. This includes bioinformatic evidence as well as clinical evidence. The ACMG Guidelines provided a framework in which to score variants based on this evidence, and while some of those scoring criteria require close consultation of the clinical context for a given patient, much of it can be automated.
In this webcast, we review how VSClinical automates the ACMG scoring guidelines while integrating the collective lab expertise from previously classified variants and preferences about genes. We will cover:
Using the ACMG Auto Classifier as part the filtering strategy for gene panels and trio workflows
How gene preferences such as the default transcript, inheritance model, and disorder are updated and saved from VSClinical and used in all future analysis
How the per-variant recommendation engine builds on the auto-classification with descriptive reasons for answering each criterion yes or no
Using the auto-interpretation to present the evidence for all scored criteria in a human-readable paragraph
Working with VSClinicals self-learning knowledgebase that incorporates previously classified variants and genes inform the interpretation of new variants!
The document discusses hypothesis testing, including defining the null and alternative hypotheses, types of errors, test statistics, and the process of hypothesis testing. Some key points:
- The null hypothesis states that a population parameter is equal to a specific value. The alternative hypothesis is paired with the null and states inequality.
- Type I errors occur when the null hypothesis is rejected when it is true. Type II errors occur when the null is not rejected when it is false.
- A test statistic is calculated based on sample data and compared to critical values to determine if the null hypothesis can be rejected.
- Hypothesis testing follows steps of stating hypotheses, choosing a significance level, collecting/analyzing data,
A database is a structured collection of data that can be easily accessed, managed, and updated. It consists of files or tables containing records with fields. Database management systems provide functions like controlling access, maintaining integrity, and allowing non-procedural queries. Major databases include GenBank, EMBL, and DDBJ for nucleotide sequences and UniProt, PDB, and Swiss-Prot for proteins. The NCBI maintains many biological databases and provides tools for analysis.
CRISPR-Cas9 is a gene editing technology that uses the bacterial immune system to cut DNA at specific locations. It allows researchers to understand, characterize, and control DNA. CRISPR-Cas9 uses an RNA-guided DNA endonuclease enzyme called Cas9 that is directed by guide RNA to cleave target DNA. It has numerous applications including modifying genes in plants and animals, developing disease resistant crops, and potentially curing genetic diseases in humans by precisely editing genes. While revolutionary, it also raises ethical concerns that must be considered and addressed.
This document provides an overview of statistical tests of significance used to analyze data and determine whether observed differences could reasonably be due to chance. It defines key terms like population, sample, parameters, statistics, and hypotheses. It then describes several common tests including z-tests, t-tests, F-tests, chi-square tests, and ANOVA. For each test, it outlines the assumptions, calculation steps, and how to interpret the results to evaluate the null hypothesis. The goal of these tests is to determine if an observed difference is statistically significant or could reasonably be expected due to random chance alone.
The Declaration of Helsinki is a set of ethical principles and guidelines for medical research involving human subjects. It was first adopted by the World Medical Association (WMA) in 1964 and has been revised multiple times, with the most recent version released in 2013. The Declaration provides a framework to protect the rights, safety, and well-being of individuals participating in research studies. Here are the key elements of the Declaration of Helsinki:
Respect for Autonomy and Informed Consent: The Declaration emphasizes the importance of respecting the autonomy of individuals and their right to make informed decisions about participating in research. It requires researchers to obtain informed consent from participants or their legally authorized representatives, ensuring they have been adequately informed about the study's purpose, procedures, potential risks and benefits, and their right to withdraw at any time.
Beneficence and Risk Assessment: Researchers have a responsibility to maximize potential benefits and minimize potential harm to research participants. The Declaration states that research protocols should be based on a thorough scientific assessment of risks and benefits and should prioritize the well-being of participants.
Ethical Review and Approval: The Declaration highlights the necessity of independent ethical review of research protocols by an appropriate research ethics committee or institutional review board (IRB). The committee should ensure that the study is scientifically valid, ethically sound, and compliant with relevant regulations and guidelines.
Privacy and Confidentiality: The Declaration emphasizes the importance of protecting the privacy and confidentiality of research participants. Researchers should ensure that participants' personal information is kept confidential, and data should be anonymized or pseudonymized whenever possible to protect participant identities.
Data and Safety Monitoring: The Declaration emphasizes the importance of ongoing data monitoring and safety assessments during the research study. Researchers should have plans in place to detect and manage any adverse events or unanticipated risks that may arise during the study.
Vulnerable Populations: Special protections are outlined for vulnerable populations, such as children, pregnant women, prisoners, and individuals with impaired decision-making capacity. Researchers should take extra precautions to ensure their well-being, and their involvement in research should be justified based on the potential benefits to their own population.
Publication and Dissemination of Results: The Declaration emphasizes the responsibility of researchers to publish and share the results of their research in a timely manner. The results should be accurately reported, and negative or inconclusive results should also be disseminated to prevent publication bias.
Dose translation from animals to humans requires consideration of factors beyond simple body weight scaling. Body surface area, pharmacokinetics, and species differences must be accounted for to safely determine starting doses in clinical trials. The NOAEL method is commonly used, identifying the no observed adverse effect level from animal studies and applying safety factors to determine a maximum recommended starting dose for humans. Proper selection of animal species and consideration of pharmacologically active doses can also inform translation of doses from animals to humans.
This document discusses T-cell epitope vaccine design through immunoinformatics. It first defines immunoinformatics as the computational study of the immune response. It then discusses types of vaccines and properties of epitopes, focusing on T-cell epitopes which are recognized by T-cells. The document explains how vaccines provide protection by stimulating memory B and T cells to quickly respond when a pathogen is encountered. It also discusses reverse vaccinology and methods for predicting epitopes, including analyzing binding affinity to MHC molecules using structure-based or sequence-based methods.
The document discusses key probability concepts including probability, binomial distribution, normal distribution, and Poisson distribution. It provides examples of how each concept is applied in pharmaceutical research and drug development, such as calculating the probability of adverse drug events, modeling drug response rates, and analyzing the number of medication errors at a pharmacy.
This document discusses high throughput screening and cell-based assays. It begins by defining high throughput screening as a process used in drug discovery to quickly assay a large number of compounds against a biological target to identify hits or leads. It then describes some key aspects of high throughput screening methodology including detection methods like spectroscopy, chromatography, and microscopy. The document outlines the advantages of cell-based assays compared to biochemical assays, noting they provide a more accurate representation using live cells. Finally, it defines the key elements of a cell-based assay as having a cellular component, a target molecule, an instrument, and informatics for data analysis.
Sequence alignment involves identifying corresponding portions of biological sequences, such as DNA, RNA, and proteins, in order to analyze similarities and differences at the level of individual bases or amino acids. This can provide insights into structural, functional, and evolutionary relationships. Sequence alignment has many applications, including searching databases for similar sequences, constructing phylogenetic trees, and predicting protein structure. It works by designing an optimal correspondence between sequences that preserves the order of residues while maximizing matches and minimizing mismatches. Quantitative measures of sequence similarity, such as Hamming distance and Levenshtein distance, calculate the number of differences between aligned sequences.
This document discusses the t test and its variations. It describes the t test as a statistical significance test introduced in 1908. The t test can be used to test single or double sample means and the significance of observed values. There are different types of t tests, including one sample t tests, independent samples t tests, and paired t tests. The document reviews the assumptions, formulas, and steps to perform the different t tests, noting they can now be easily conducted with computers.
Satyaki Aparajit Mishra presented on the topic of standard error and predictability limits. Standard error is used to estimate the standard deviation from a sample. It is calculated by dividing the standard deviation by the square root of the sample size. A larger standard error means the sample mean is less reliable at estimating the population mean. Standard error helps determine how far sample estimates may be from the true population values. Mishra discussed estimating standard error from a single sample and how standard error is used to test hypotheses. He provided an example of testing if a coin flip was unbiased using the standard error of the proportion of heads observed.
PubMed is a free database of over 23 million citations and abstracts for biomedical literature from Medline, life sciences journals, and online books. It is maintained by the National Center for Biotechnology Information (NCBI) at the U.S. National Library of Medicine (NLM). PubMed provides bibliographic information and links to full-text content from publishers and libraries. Users can search PubMed using keywords, controlled vocabularies like MeSH, or advanced search techniques and filters to find relevant journal articles and resources.
Signal Management and Risk Assessment in PharmacovigilanceClinosolIndia
油
Signal management and risk assessment are critical components of pharmacovigilance, aimed at identifying and evaluating potential safety concerns associated with medicinal products. These processes help ensure the ongoing monitoring of product safety and the implementation of appropriate risk minimization strategies. Here's an overview of signal management and risk assessment in pharmacovigilance:
Signal Management:
A signal in pharmacovigilance refers to information that suggests a potential causal relationship between a medicinal product and an adverse event, either previously unrecognized or incompletely understood. Signal management involves the systematic detection, evaluation, and response to these potential safety signals. The goal is to determine whether further investigation is warranted and to take appropriate actions to mitigate risks if necessary.
Signal Management Process:
Signal Detection: Signals can be detected through various methods, including spontaneous reporting databases, literature review, data mining techniques, and cumulative analysis of safety data. Unusual patterns, unexpected associations, or an increase in the frequency of specific adverse events may trigger the need for further investigation.
Signal Evaluation: Once a signal is detected, it undergoes a comprehensive evaluation. This involves analyzing available data, conducting causality assessments, reviewing clinical trial results, and considering factors such as patient demographics, medical history, and concomitant medications.
Signal Validation: Validating a signal involves confirming its credibility and clinical relevance. This step may require additional data collection, case validation, and collaboration between various stakeholders, including regulatory authorities.
Signal Prioritization: Not all signals warrant the same level of attention. Signals are prioritized based on factors such as the severity of the adverse event, the strength of the association, and the potential impact on patient safety.
Risk-Benefit Assessment: A thorough benefit-risk assessment is conducted to weigh the potential risks associated with the signal against the known benefits of the medicinal product. This assessment informs regulatory decisions and the need for further actions.
Risk Minimization: If the signal is deemed credible and significant, risk minimization strategies may be implemented. These strategies could include changes to product labeling, communication to healthcare professionals and patients, and other measures to ensure the safe use of the product.
This document discusses correlation and different aspects of studying correlation. It defines correlation as the association or relationship between two variables that do not cause each other. It describes different types of correlation including positive, negative, linear, non-linear, simple, multiple and partial correlation. It also discusses various methods of studying correlation including graphic methods like scattered diagrams and correlation graphs, and algebraic methods like Karl Pearson's correlation coefficient and Spearman's rank correlation coefficient. The document explains concepts like coefficient of determination and hypothesis testing in correlation. It emphasizes that correlation indicates association but does not necessarily imply causation between variables.
Introduction
Definition
History
Principle
Components of bioinformatics
Bioinformatics databases
Tools of bioinformatics
Applications of bioinformatics
Molecular medicine
Microbial genomics
Plant genomics
Animal genomics
Human genomics
Drug and vaccine designing
Proteomics
For studying biomolecular structures
In- silico testing
Conclusion
References
FDA Guidelines for Drug Development & Approvalrahimbrave
油
The document discusses the drug development and approval process in the United States. It describes the roles and responsibilities of the Food and Drug Administration (FDA) in regulating drugs, medical devices, and other products. It then outlines the various phases of clinical trials (Phases I-IV) that drugs must go through to test for safety and efficacy before FDA approval. It also discusses the processes for approving generic drugs, biological products, and modifications to approved drugs.
The document discusses the history and definition of degrees of freedom. It states that the earliest concept of degrees of freedom was noted in the 1800s in the works of mathematician Carl Friedrich Gauss. The modern understanding was developed by statistician William Sealy Gosset in 1908, though he did not use the term. The term "degrees of freedom" became popular after English biologist Ronald Fisher began using it in 1922 when publishing reports on his work developing chi squares. Degrees of freedom represent the number of values in a study that can vary freely. They are important for understanding chi-square tests and the validity of the null hypothesis.
Automating the ACMG Guidelines with VSClinicalGolden Helix
油
Clinical Genetic testing requires a complex analysis using the totality of our knowledge about the clinical relevance of a variant and a gene. This includes bioinformatic evidence as well as clinical evidence. The ACMG Guidelines provided a framework in which to score variants based on this evidence, and while some of those scoring criteria require close consultation of the clinical context for a given patient, much of it can be automated.
In this webcast, we review how VSClinical automates the ACMG scoring guidelines while integrating the collective lab expertise from previously classified variants and preferences about genes. We will cover:
Using the ACMG Auto Classifier as part the filtering strategy for gene panels and trio workflows
How gene preferences such as the default transcript, inheritance model, and disorder are updated and saved from VSClinical and used in all future analysis
How the per-variant recommendation engine builds on the auto-classification with descriptive reasons for answering each criterion yes or no
Using the auto-interpretation to present the evidence for all scored criteria in a human-readable paragraph
Working with VSClinicals self-learning knowledgebase that incorporates previously classified variants and genes inform the interpretation of new variants!
The document discusses hypothesis testing, including defining the null and alternative hypotheses, types of errors, test statistics, and the process of hypothesis testing. Some key points:
- The null hypothesis states that a population parameter is equal to a specific value. The alternative hypothesis is paired with the null and states inequality.
- Type I errors occur when the null hypothesis is rejected when it is true. Type II errors occur when the null is not rejected when it is false.
- A test statistic is calculated based on sample data and compared to critical values to determine if the null hypothesis can be rejected.
- Hypothesis testing follows steps of stating hypotheses, choosing a significance level, collecting/analyzing data,
A database is a structured collection of data that can be easily accessed, managed, and updated. It consists of files or tables containing records with fields. Database management systems provide functions like controlling access, maintaining integrity, and allowing non-procedural queries. Major databases include GenBank, EMBL, and DDBJ for nucleotide sequences and UniProt, PDB, and Swiss-Prot for proteins. The NCBI maintains many biological databases and provides tools for analysis.
CRISPR-Cas9 is a gene editing technology that uses the bacterial immune system to cut DNA at specific locations. It allows researchers to understand, characterize, and control DNA. CRISPR-Cas9 uses an RNA-guided DNA endonuclease enzyme called Cas9 that is directed by guide RNA to cleave target DNA. It has numerous applications including modifying genes in plants and animals, developing disease resistant crops, and potentially curing genetic diseases in humans by precisely editing genes. While revolutionary, it also raises ethical concerns that must be considered and addressed.
This document provides an overview of statistical tests of significance used to analyze data and determine whether observed differences could reasonably be due to chance. It defines key terms like population, sample, parameters, statistics, and hypotheses. It then describes several common tests including z-tests, t-tests, F-tests, chi-square tests, and ANOVA. For each test, it outlines the assumptions, calculation steps, and how to interpret the results to evaluate the null hypothesis. The goal of these tests is to determine if an observed difference is statistically significant or could reasonably be expected due to random chance alone.
The Declaration of Helsinki is a set of ethical principles and guidelines for medical research involving human subjects. It was first adopted by the World Medical Association (WMA) in 1964 and has been revised multiple times, with the most recent version released in 2013. The Declaration provides a framework to protect the rights, safety, and well-being of individuals participating in research studies. Here are the key elements of the Declaration of Helsinki:
Respect for Autonomy and Informed Consent: The Declaration emphasizes the importance of respecting the autonomy of individuals and their right to make informed decisions about participating in research. It requires researchers to obtain informed consent from participants or their legally authorized representatives, ensuring they have been adequately informed about the study's purpose, procedures, potential risks and benefits, and their right to withdraw at any time.
Beneficence and Risk Assessment: Researchers have a responsibility to maximize potential benefits and minimize potential harm to research participants. The Declaration states that research protocols should be based on a thorough scientific assessment of risks and benefits and should prioritize the well-being of participants.
Ethical Review and Approval: The Declaration highlights the necessity of independent ethical review of research protocols by an appropriate research ethics committee or institutional review board (IRB). The committee should ensure that the study is scientifically valid, ethically sound, and compliant with relevant regulations and guidelines.
Privacy and Confidentiality: The Declaration emphasizes the importance of protecting the privacy and confidentiality of research participants. Researchers should ensure that participants' personal information is kept confidential, and data should be anonymized or pseudonymized whenever possible to protect participant identities.
Data and Safety Monitoring: The Declaration emphasizes the importance of ongoing data monitoring and safety assessments during the research study. Researchers should have plans in place to detect and manage any adverse events or unanticipated risks that may arise during the study.
Vulnerable Populations: Special protections are outlined for vulnerable populations, such as children, pregnant women, prisoners, and individuals with impaired decision-making capacity. Researchers should take extra precautions to ensure their well-being, and their involvement in research should be justified based on the potential benefits to their own population.
Publication and Dissemination of Results: The Declaration emphasizes the responsibility of researchers to publish and share the results of their research in a timely manner. The results should be accurately reported, and negative or inconclusive results should also be disseminated to prevent publication bias.
Dose translation from animals to humans requires consideration of factors beyond simple body weight scaling. Body surface area, pharmacokinetics, and species differences must be accounted for to safely determine starting doses in clinical trials. The NOAEL method is commonly used, identifying the no observed adverse effect level from animal studies and applying safety factors to determine a maximum recommended starting dose for humans. Proper selection of animal species and consideration of pharmacologically active doses can also inform translation of doses from animals to humans.
This document discusses T-cell epitope vaccine design through immunoinformatics. It first defines immunoinformatics as the computational study of the immune response. It then discusses types of vaccines and properties of epitopes, focusing on T-cell epitopes which are recognized by T-cells. The document explains how vaccines provide protection by stimulating memory B and T cells to quickly respond when a pathogen is encountered. It also discusses reverse vaccinology and methods for predicting epitopes, including analyzing binding affinity to MHC molecules using structure-based or sequence-based methods.
The document discusses key probability concepts including probability, binomial distribution, normal distribution, and Poisson distribution. It provides examples of how each concept is applied in pharmaceutical research and drug development, such as calculating the probability of adverse drug events, modeling drug response rates, and analyzing the number of medication errors at a pharmacy.
This document discusses high throughput screening and cell-based assays. It begins by defining high throughput screening as a process used in drug discovery to quickly assay a large number of compounds against a biological target to identify hits or leads. It then describes some key aspects of high throughput screening methodology including detection methods like spectroscopy, chromatography, and microscopy. The document outlines the advantages of cell-based assays compared to biochemical assays, noting they provide a more accurate representation using live cells. Finally, it defines the key elements of a cell-based assay as having a cellular component, a target molecule, an instrument, and informatics for data analysis.
1) The document discusses the opportunity for technology to improve organizational efficiency and transition economies into a "smart and clean world."
2) It argues that aggregate efficiency has stalled at around 22% for 30 years due to limitations of the Second Industrial Revolution, but that digitizing transport, energy, and communication through technologies like blockchain can help manage resources and increase efficiency.
3) Technologies like precision agriculture, cloud computing, robotics, and autonomous vehicles may allow for "dematerialization" and do more with fewer physical resources through effects like reduced waste and need for transportation/logistics infrastructure.
This coffee blend is smooth and brims with sweet notes of chocolate and hazelnut. It comes from Finca La Victoria in Honduras, located at 1200-1600 meters in the volcanic soil of the Marcala region. The farm uses sustainable organic practices like shade-grown trees and crop diversification that intensify the coffee's flavors.
This dark roast coffee from BOCCACoffee Roasters has spicy, sweet caramel, and chocolate flavors that create a pleasantly surprising explosion in the mouth. The blend consists of Brazilian coffee from the Recreio farm in the Vale de Grama region and Colombian coffee from the Inga Aponte farm in Nari単o. Both farms are praised for their high quality and sustainable practices.
This coffee blend is described as versatile and full-bodied, with notes of milk chocolate, honey and berries. It consists of three certified organic coffees from Brazil and Ethiopia that are naturally processed. The combination creates a sweet yet acidic cup profile with flavors of chocolate, berries, and milk chocolate.
Presentatie bouwreis Cambodja - Marcel van WijkJeroen de Bruin
油
1) The document describes a volunteer trip to Cambodia where the author helped build a house for a family.
2) The family consisted of grandparents taking care of their two grandchildren and two orphans, with the grandparents having to sleep outside due to lack of space.
3) Over the course of several days, the volunteers constructed the foundation, floor, walls and roof of the new house to provide better living conditions for the family.
Op 27 september 2016 heeft de voorzieningenrechter van Rechtbank Rotterdam vonnis gewe zen in een door de Vereniging Nederlandse Verkeersvliegers (VNV) tegen de KLM aangespannen kort geding. Onderwerp van het geschil vormen de bijstortingsverplichtingen van de KLM in het pensioenfonds voor de KLM-piloten. De KLM is in dit kort geding in het gelijk gesteld, maar daarmee is deze discussie zeker nog niet afgerond. Niet alleen heeft de VNV hoger beroep inge足steld, maar bovendien zit er ook nog een procedure aan te komen tussen het pensioenfonds voor de KLM-piloten en de KLM. De KLM heeft namelijk de uitvoeringsovereenkomst met het pensioenfonds opgezegd in verband met de hoogte van de bijstortingsverplichtingen.
Disruptive Finance 2016 (supplement to Het Financieele Dagblad)Jeroen de Bruin
油
This document discusses the regulatory challenges faced by FinTech startups. It notes that FinTech involves introducing new business models into the heavily regulated financial services industry. The regulations were designed to reduce risks but can undermine startups by requiring them to be risk averse. Two lawyers from Clifford Chance, Alvin Khodabaks and Marian Scheele, provide insights. Scheele notes many FinTech startups are shocked by the extensive regulations around providing financial services like credit and payments. However, the lawyers also point out that regulations do not make business impossible, especially with the harmonization of rules in Europe. PSD2 will help payment providers operate across Europe, but rules for other FinTech solutions like robo-advice still
Telegraaf 7 februari 2015: ''Redding V&D juridisch lastig''Jeroen de Bruin
油
Ilse van Gasteren, advocaat bij Clifford Chance, vertelt over de wetswijziging die 2016 van kracht zou moeten worden waarbij dreigende faillissementen anders dan nu afgehandeld kunnen worden.
Telegraaf 7 februari 2015: ''Redding V&D juridisch lastig''Jeroen de Bruin
油
FD Droomweekend managing partner Bas Boris Visser
1. 17 mei 2014 息 Het Financieele Dagblad
droomweekenddroomweekendEenidealeagendazonderbeperkingenvantijd,afstandofgeld
BasBoris
Visser(46)Visser(46)
Is:managing partner
CliffordChance
Reistnooitzonder:
Een lekkerwegleesboek uit
de kiosk op Schiphol
Mooisteherinneringaan:
LAubergede Sedonaaaneen
rivier ten zuidenvan de Grand
Canyon. Welogeerden erin een
blokhut en het eten wasongelo-
felijk lekker
Opgetekend door:
Jacqueline Bosboom
vrijdag19.00uurvrijdag19.00uur
MalawienBeiroet
De wodka-tonic
smaakt ons uitste-
kend. Metwatcolle-
gas van kantoorben
ik net teruggekeerd
van eenwandelsa-
fari. Voor de Nyala
Lodge zien we de zon
ondergaan. Deze
safaribestemming
is misschien niet de
spectaculairste, maar
wel zo gemoedelijk.
En de braaiis er
fantastisch.
Voor het echte uit-
gaansleven ontmoet
ik rond een uur oftien
eengroepvrienden
in deMusicHallin
Beiroet. In deze ca-
bareteske nachtclub
worden we opgeno-
mendoor inwoners
van de stad die onder
het carpediem-motto
uitbundig feesten
op deopzwepende
livemuziek.
tinyurl.com/Nyala-
Lodge
themusichall.com
zaterdag08.30uur
LosAngeles
Bij het ontbijtop
hetbalkon van het
houtenhotelShutters
on the Beach inSanta
Monica zien wede
eerste surfers al in de
branding. Bij onze
poging later in de
ochtend liggen mijn
zoon Ivan en ik meer
op de plank danwe
erop staan, maar dat
mag de pret nietdruk-
ken. De fietstocht met
LosAngele
mijn jongstedochter
AnaBelen langs de
kust gaat me gemak-
kelijker af. Van achter
op detandem vertelt
ze me voortdurend
wat we zien.
shuttersonthebeach.
com
zaterdag
13.00uur13.00uur
Alicante
Elke keer is het een
feestom bijElPiripi
te eten.In dit Spaanse
tapasrestaurant met
tl-verlichtingzitten
Maria, mijnSpaanse
vrouw, en ik aan de
verrukkelijkste hapjes.
Erbijdrinken we een
ca単a, eentapbiertje.
Bepakt met rugzak-
ken wandelenNina,
eenvanmijn dochters,
en ik vervolgens vanuit
onshuis in Alteala
Vella deSierra Bernia
in. Een ideale manier
om bij te praten.
noumanolin.com
tinyurl.com/bernia-
wandeling
zaterdag20.30uur
EtenaanhetSpaansestrand
zaterdag20.30uur
Op vijf meter van
hetwaterstaande
lange tafels van mijn
favoriete strand-
tentje,Chiringuito
Merendero Arrecife
bijCapNegret.Uit de
stacaravan wordende
heerlijkste gerechten
tevoorschijn getoverd
voor bij het vlees en
de vis van de barbe-
cue. Vrienden uit alle
hoeken van dewereld
schuiven aan.
tinyurl.com/
strandtentje
Mallorca
zondag08.00uur
Mallorca
Maria en ik ontbijten
op het dakterras van
de torenkamer van
boetiekhotel La Re-
sidencia inhet kun-
stenaarsdorp Deia.
Vanhieruit lopen
we het Son Castell坦-
pad naar Soll竪r, een
prachtige wandeling
door het bergachtige
noordwesten van het
eiland.
hotel-laresidencia.
com
tinyurl.com/SonCas-
tello
ExpoinBologna
zondag 11.30uur
ExpoinBologna
Binnenkorthan-
gende Hollandse
meesters uit het
Mauritshuis weer
op hun vertrouwde
plek in Den Haag.
Wijbekijken derei-
zendetentoonstel-
ling in het Palazzo
Fava inBologna.
tinyurl.com/Pa-
lazzofava
zondag14.00uur
Fo
ZeileninhetCaribischgebied
Inde verte zien we
Sint-Maarten nog
liggen. Daar ben ik
met eenaantal goede
vriendenaan boord
gestapt vaneenhuur-
boot. Vanwege de
goede herinneringen
doen we onze zeiltrip
in het Caribisch
gebied naarSaint-
Barth nogeens over.
Onderweg gaanwe bij
diverseeilandjesvoor
anker envarenwe in
het bijbootjenaar de
mooiste strandjes.
Zeileninhe
Met Maria en de
kinderen sluit ik
daarna in het hart
vanSanFrancisco
het weekend af. Bij
steakrestaurant Mor-
tons eetik een New
York Strip, ofwel een
flinksoort entrecote
met heerlijkefrietjes.
themoorings.nl
mortons.com
Fo
d
Foto:gettyimages
les
Foto:aFp
hetCaribischgebied
Foto:gettyimages